Literature DB >> 6385887

The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro.

W M Watkins, D G Sixsmith, J D Chulay.   

Abstract

Using an in vitro radioisotopic method, the activity was measured of proguanil, its metabolites cycloguanil and p-chlorophenylbiguanide (PBG), pyrimethamine, and chloroquine against seven Kenyan and three South East Asian strains of Plasmodium falciparum. Five Kenyan isolates were sensitive to both pyrimethamine and cycloguanil in vitro, while the Smith and two Kenyan strains were resistant to both these drugs. Cross-resistance was incomplete: the Camp strain was resistant to pyrimethamine but not cycloguanil, and the FVO strain was resistant to cycloguanil but not pyrimethamine. Both proguanil and PBG exhibited weak antimalarial activity in vitro, but inhibitory blood levels of either compound are unlikely to occur after a normal human dose of proguanil. The results indicate that the activity of proguanil against P. falciparum is due entirely to the action of its active metabolite cycloguanil.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385887     DOI: 10.1080/00034983.1984.11811816

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  12 in total

Review 1.  A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.

Authors:  Hazem Elewa; Kyle John Wilby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

2.  Potent antimalarial activity of the alkaloid nitidine, isolated from a Kenyan herbal remedy.

Authors:  D M Gakunju; E K Mberu; S F Dossaji; A I Gray; R D Waigh; P G Waterman; W M Watkins
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

3.  Transformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanil.

Authors:  D A Fidock; T E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

4.  Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance.

Authors:  S J Foote; D Galatis; A F Cowman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

5.  Alternative oxidase inhibitors potentiate the activity of atovaquone against Plasmodium falciparum.

Authors:  A D Murphy; N Lang-Unnasch
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

6.  In vitro activity of cycloguanil against African isolates of Plasmodium falciparum.

Authors:  L K Basco; O Ramiliarisoa; P Ringwald; J C Doury; J Le Bras
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

7.  Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.

Authors:  Ramatoulie E Janha; Fatoumatta Sisay-Joof; Majidah Hamid-Adiamoh; Archibald Worwui; Hannah L Chapman; Hyginus Opara; Sam Dunyo; Paul Milligan; Kirk Rockett; Peter Winstanley; Munir Pirmohamed; Ann K Miller; David J Conway; Robert T Walton
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

8.  Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

Authors:  R Setiabudy; M Kusaka; K Chiba; I Darmansjah; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

9.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.

Authors:  R McGready; K Stepniewska; E Seaton; T Cho; D Cho; A Ginsberg; M D Edstein; E Ashley; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

Review 10.  Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria.

Authors:  Kate McKeage; Lesley Scott
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.